Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus TKI for 2nd-line Advanced HCC
NCT06363006Phase 1Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Mar 2024
- Primary completion
- Jan 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cadonilimab in hepatocellular carcinoma (HCC), sponsored by Peking Union Medical College Hospital. Primary endpoints: Objective Response Rate at 3 years and Progression-Free Survival at 1.5 years. Started Mar 2024; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06363006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06363006.